An earlier version of this article misidentified the manufacturer of the COVID-19 vaccine. Story fixed. European stocks and US stock futures fell on Friday as investors watched eagerly the stimulus package and the Brexit talks exit from Washington, and they absorbed mixed news on the COVID-19 vaccine. Stocks Europe 600 index SXXP, -1.38% down 0.8% to 389.89, the index fell 1% during the week. German DAX DAX, -1.97% 1%, French CAC 40 PX1, -1.31% 0.9%, and FTSE 100 UKX, -1.09% 0.5% lower. FDSE losses eased by 0.5% to-0.86% against the dollar after UK Prime Minister Boris Johnson said the country needed the post-Brexit trade agreement with the EU to win. Will not happen. The weaker pound will increase the competitiveness of the goods and services of multinational companies listed in London. “There is now a strong possibility – a strong possibility – that we will find a solution similar to Australia’s relationship with the EU, rather than Canada’s relationship with the EU,” Johnson said. The video address was released by his office. The new deadline for negotiations on a trade deal between the EU and the UK Wall Street is set for Sunday, with the Dow futures YM00, down 0.2.78% to 142 points. Discussions on a two-party $ 908 billion pandemic relief package in Washington on Thursday showed signs of a struggle. Economic data have shown a sharp rise in unemployment claims, which may be due to the uncontrolled second wave of the COVID-19 epidemic in US stocks in Europe, with the European Central Bank expanding its assets since Thursday’s news that the region is battling the COVID-19 epidemic. The moves were mostly in line with expectations. “Severe corona virus numbers across Europe weigh in on risk appetite this morning. The number of new COVID-19 infections has reached a record high in Germany, and severe locks are now appearing across Europe,” Axis market analyst Milan Gadkovic wrote in a note to customers before and focusing on vaccine news. , Sanofi SNY, + 0.26% SAN, -2.34% down 2.3%, following a statement by French pharmaceutical company Covit-19 vaccine treatment with UK pharmaceutical company GlaxoSmithKline GSK, + 0.18%. GSK delayed + 0.34% due to insufficient immunity in the elderly, while shares of Glososmithkline rose 0.7%. ”As governments and central banks take decisive action to combat the negative effects of long-term locks, the market participates in ignoring the immediate effects. It’s getting harder for people, “said Gudkovic. Vaccine relapses occurred elsewhere, as biopharmaceutical company CSL CSL dropped its program for COVID-19 vaccination from -3.24% after false positive results for HIV tests. On the most positive note, as of late Thursday, the U.S. Food and Drug Administration Advisory Board has approved emergency approval for the COVID-19 vaccine candidate from the pharmaceutical company Pfizer PFE, -0.29% and its partner BioNTech PNTX, + 5.48% Voted in favor of the recommendation. . The FDA may make its decision soon on Friday. The UK began releasing its vaccine plan this week. Among the most active stocks, shares of Ericsson ERIC fell -0.41% to 7%, following a lawsuit filed by Swedish telecommunications-equipment dealer Samsung Electronics against 005930, + 0.69%, for breach of contract. Ericsson warned that late royalty payments and legal costs could cost between 1 billion and 1.5 billion Swedish kronor ($ 118.1 million – $ 177.2 million) a quarter. Shares of Randstadt Rand rose close to +4.19% to 6% after the Dutch recruiter announced that it had recovered faster than expected in the fourth quarter of the year so far and raised guidance. Shares of Rolls-Royce RR plunged more than 4% to -8.74% after the British aircraft-engine maker said it expects bigger remittances than expected at $ 4.2 billion ($ 5.58 billion) in 2020 as the corona virus infection continues to rise. They have reduced the recovery for air travel. Kனிniglijke Alt Delhais AD, -0.98% It has a $ 1 billion ($ 1.21 billion) stability loan facility that helps Amsterdam-listed food retailer reduce waste and carbon emissions and provide financial flexibility amid epidemics. The stock fell 0.6%. .
Source